More than 2,300 patients are helped every day2
IN 2019,2 the HorizonCares program provided co-pay support for close to 850,000 patients
3 ways to support your commercially insured patients today
E-prescribe to One Point Patient Care, 8130 Lehigh Ave., Morton Grove, IL 60053.
Pharmacy ID
NCPDP/NABP: 1482621
NPI: 1912151515
Please fax an SMN form to 1-844-308-9412. Call 866-323-1490 with any questions
Ask your sales representative for information on participating pharmacies
Have pharmacist call
844-HZ-CARE1 for money-saving offers
Download documents about how to submit a Prior Authorization and how HorizonCares works.
Everything you need to start a Prior Authorization for DUEXIS.
213.0 KB
Everything you need to start a Prior Authorization for PENNSAID 2%.
196.0 KB
Everything you need to start a Prior Authorization for RAYOS.
164.0 KB
Learn more about how HorizonCares helps patients get the medication they need quickly and affordably.
92.0 KB
Share this overview of how the HorizonCares program works with your patients.
139.0 KB
More than 2,300 patients are helped every day2
IN 2019,2 the HorizonCares program provided co-pay support for close to 850,000 patients
*Subject to eligibility rules and restrictions.
†HorizonCares calls 100% of patients when correct patient contact information is provided.
Start your patients on therapy with samples of a Horizon Inflammation Care product.
Request samplesGet more information by having your representative come to your practice.
Request a representativeDUEXIS® (ibuprofen and famotidine), a combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain of osteoarthritis of the knee(s).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
RAYOS is a corticosteroid indicated:
Please see full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
DUEXIS® (ibuprofen and famotidine), a combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain of osteoarthritis of the knee(s).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
RAYOS is a corticosteroid indicated:
Please see full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.